{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:47:45Z","timestamp":1789519665536,"version":"build-2803163510"},"reference-count":38,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"12","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.1167\/tvst.14.12.20","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T15:30:41Z","timestamp":1766417441000},"page":"20","source":"Crossref","is-referenced-by-count":1,"title":["Structure-Function Correlation Using a Targeted Image-Guided Microperimetry Approach for Retinal Atrophic Diseases: A Methods Study"],"prefix":"10.1167","volume":"14","author":[{"given":"Rubbia","family":"Afridi","sequence":"first","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sohail","family":"Halim","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmet","family":"Yucel","sequence":"additional","affiliation":[{"name":"Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha Zahid","family":"Fazal","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholood","family":"Janjua","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Campigotto","sequence":"additional","affiliation":[{"name":"Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mahmood","family":"Shah","sequence":"additional","affiliation":[{"name":"Emplify Health, La Crosse, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir Jamal","family":"Sepah","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"1","key":"bib1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-vision-101922-045110","article-title":"Informing endpoints for clinical trials of geographic atrophy","volume":"10","author":"Lad","year":"2024","journal-title":"Annu Rev Vis Sci"},{"issue":"12","key":"bib2","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/eye.2015.142","article-title":"Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)","volume":"29","author":"Do","year":"2015","journal-title":"Eye (Lond)"},{"issue":"10411","key":"bib3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"bib4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"bib5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.preteyeres.2008.07.003","article-title":"Use of fundus perimetry (microperimetry) to quantify macular sensitivity","volume":"27","author":"Rohrschneider","year":"2008","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"bib6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2415-6-24","article-title":"Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population?","volume":"6","author":"Owen","year":"2006","journal-title":"BMC Ophthalmol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2018.03.006","article-title":"Reliability and construct validity of the NEI VFQ-25 in a subset of patients with geographic atrophy from the phase 2 Mahalo study","volume":"190","author":"Sivaprasad","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2025.02.012","article-title":"Visual function benefit after treatment with pegcetacoplan: microperimetry analysis from the phase 3 Oaks trial","volume":"273","author":"Chakravarthy","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"bib9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.survophthal.2019.01.014","article-title":"Microperimetry for geographic atrophy secondary to age-related macular degeneration","volume":"64","author":"Csaky","year":"2019","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"bib10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"bib11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/APO.0000000000000597","article-title":"Microperimetry in retinal diseases","volume":"12","author":"Horie","year":"2023","journal-title":"Asia Pac J Ophthalmol"},{"issue":"5","key":"bib12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000515148","article-title":"Clinical perspectives and trends: microperimetry as a trial endpoint in retinal disease","volume":"244","author":"Yang","year":"2021","journal-title":"Ophthalmologica"},{"issue":"1","key":"bib13","doi-asserted-by":"publisher","first-page":"100351","DOI":"10.1016\/j.xops.2023.100351","article-title":"Macular sensitivity endpoints in geographic atrophy: exploratory analysis of Chroma and Spectri clinical trials","volume":"4","author":"Chang","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"14","key":"bib14","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1167\/iovs.16-20037","article-title":"Feasibility of macular integrity assessment (MAIA) microperimetry in children: sensitivity, reliability, and fixation stability in healthy observers","volume":"57","author":"Jones","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2017.12.002","article-title":"Evaluating the usefulness of MP-3 microperimetry in glaucoma patients","volume":"187","author":"Matsuura","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"bib16","doi-asserted-by":"publisher","first-page":"BIO268","DOI":"10.1167\/iovs.17-21710","article-title":"Metrics and acquisition modes for fixation stability as a visual function biomarker","volume":"58","author":"Sch\u00f6nbach","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"bib17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.12.6.4","article-title":"Microperimetry as an outcome measure in RPGR- associated retinitis pigmentosa clinical trials","volume":"12","author":"Taylor","year":"2023","journal-title":"Trans Vis Sci Tech"},{"issue":"11","key":"bib19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaophthalmol.2017.4152","article-title":"Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective progression of Stargardt Disease Study (ProgStar Report No. 9)","volume":"135","author":"Strauss","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"bib20","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1097\/IAE.0000000000001283","article-title":"Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration","volume":"36","author":"Sadda","year":"2016","journal-title":"Retina"},{"issue":"2","key":"bib21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000510507","article-title":"Growth rate of geographic atrophy secondary to age-related macular degeneration: a meta-analysis of natural history studies and implications for designing future trials","volume":"64","author":"Wang","year":"2021","journal-title":"Ophthalmic Res"},{"issue":"4","key":"bib22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/08820538.2019.1622025","article-title":"Microperimetry in three inherited retinal disorders","volume":"34","author":"Bagdonaite-Bejarano","year":"2019","journal-title":"Semin Ophthalmol"},{"issue":"7","key":"bib23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamaophthalmol.2017.1162","article-title":"Macular sensitivity measured with microperimetry in Stargardt disease in the progression of atrophy secondary to Stargardt disease (ProgStar) study: Report No. 7","volume":"135","author":"Sch\u00f6nbach","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta Experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"bib26","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"bib27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"bib28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ceo.13458","article-title":"Progression of retinitis pigmentosa on multimodal imaging: The PREP-1 study","volume":"47","author":"Iftikhar","year":"2019","journal-title":"Clin Exper Ophthalmol"},{"issue":"1","key":"bib29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13816810.2020.1827442","article-title":"Exploring microperimetry and autofluorescence endpoints for monitoring disease progression in PRPF31-associated retinopathy","volume":"42","author":"Roshandel","year":"2021","journal-title":"Ophthalmic Genet"},{"issue":"7","key":"bib30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.9.7.2","article-title":"Advancing clinical trials for inherited retinal diseases: recommendations from the Second Monaciano Symposium","volume":"9","author":"Thompson","year":"2020","journal-title":"Trans Vis Sci Tech"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.survophthal.2019.01.014","article-title":"Microperimetry for geographic atrophy secondary to age-related macular degeneration","volume":"64","author":"Csaky","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"100351","DOI":"10.1016\/j.xops.2023.100351","article-title":"Macular sensitivity endpoints in geographic atrophy: exploratory analysis of Chroma and Spectri Clinical Trials","volume":"4","author":"Chang","year":"2023","journal-title":"Ophthalmol Sci."},{"issue":"1","key":"bib33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40942-019-0176-9","article-title":"Microperimetry and OCT angiography evaluation of patients with ischemic diabetic macular edema treated with monthly intravitreal bevacizumab: a pilot study","volume":"5","author":"Pereira","year":"2019","journal-title":"Int J Retin Vitr"},{"issue":"8","key":"bib34","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3390\/jcm13082219","article-title":"The natural history of retinal sensitivity loss in diabetic macular ischemia over one year evaluated by microperimetry","volume":"13","author":"Tsai","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"bib35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.survophthal.2017.05.007","article-title":"The use of microperimetry in assessing visual function in age-related macular degeneration","volume":"63","author":"Cassels","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"bib36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1097\/IAE.0b013e3182365a24","article-title":"Measuring retinal sensitivity with the microperimeter in patients with diabetes","volume":"32","author":"Nittala","year":"2012","journal-title":"Retina"},{"issue":"12","key":"bib37","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.ophtha.2011.08.006","article-title":"Visual function in glaucoma","volume":"118","author":"Markowitz","year":"2011","journal-title":"Ophthalmology"},{"issue":"2","key":"bib38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.66.2.6","article-title":"Targeted microperimetry grids for focal lesions in intermediate AMD: PINNACLE Study Report 7","volume":"66","author":"Futterknecht","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/11744023_32","article-title":"SURF: Speeded up robust features","volume-title":"Computer Vision \u2013 ECCV 2006","author":"Bay","year":"2006"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2811268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T15:30:42Z","timestamp":1766417442000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2811268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.14.12.20","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}